Gene Expressing Profiling of Iris Melanomas

Department of Ophthalmology & Visual Sciences, Washington University School of Medicine, St. Louis, Missouri.
Ophthalmology (Impact Factor: 6.14). 01/2013; 120(1):213-213.e3. DOI: 10.1016/j.ophtha.2012.08.016
Source: PubMed
2 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: To evaluate outcomes after ophthalmic plaque radiation therapy for small choroidal melanomas. DESIGN: Retrospective study, case series. PARTICIPANTS: Seventy-two patients with choroidal melanomas ≥1.5 and ≤2.4 mm apical height and ≤10 mm width treated between 2002 and 2012, with a minimum follow-up of 8 months. METHODS: All patients were treated with palladium-103 plaque brachytherapy. Mean radiation dose to the tumor apex was 82.4 Gy (range, 70.0-102 Gy). MAIN OUTCOME MEASURES: Local control, radiation complications, visual acuity, and metastatic rate. RESULTS: Plaque radiotherapy provided 100% local tumor control and eye retention at a mean 54 months of observation (95% confidence interval, 46-63 months). The most common long-term brachytherapy-related complications were radiation maculopathy (43.1%) and radiation optic neuropathy (20.8%) developing at a mean of 27 months (range, 9-72 months) after irradiation. In this series, 94.4% of patients maintained 20/200 or better vision. There has been no small choroidal melanoma-related metastasis. CONCLUSIONS: Palladium-103 plaque radiation therapy offered excellent local control and visual acuity outcomes for patients with small choroidal melanoma. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
    No preview · Article · Jun 2013 · Ophthalmology